Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 5
2005 1
2006 3
2007 3
2008 2
2009 4
2010 3
2011 6
2012 8
2013 7
2014 8
2015 11
2016 6
2017 9
2018 10
2019 13
2020 9
2021 5
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Orlando L, Maiello E, Orditura M, Diana A, Antoniol G, Morritti MG, Aieta M, Ciccarese M, Pisconti S, Bordonaro R, Russo A, Febbraro A, Schiavone P, Quaranta A, Caliolo C, Loparco D, Cinefra M, Colucci G, Cinieri S; Gruppo Oncologico dell’Italia Meridionale (GOIM). Orlando L, et al. Among authors: orditura m. Breast. 2024 Apr 5;75:103725. doi: 10.1016/j.breast.2024.103725. Online ahead of print. Breast. 2024. PMID: 38615483 Free PMC article.
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review.
Parisi S, Gambardella C, Iovino F, Ruggiero R, Lucido FS, Nesta G, Tolone S, Brusciano L, Fisone F, Mongardini FM, Cozzolino G, Della Corte CM, Napolitano S, Orditura M, Esposito R, Docimo L. Parisi S, et al. Among authors: orditura m. J Clin Med. 2024 Jan 18;13(2):567. doi: 10.3390/jcm13020567. J Clin Med. 2024. PMID: 38256700 Free PMC article. Review.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Retraction notice to "Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors" [Lung Cancer 71 (2011) 283-290].
Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F. Morgillo F, et al. Among authors: orditura m. Lung Cancer. 2023 Jul;181:107226. doi: 10.1016/j.lungcan.2023.107226. Epub 2023 May 9. Lung Cancer. 2023. PMID: 37167905 No abstract available.
NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
Zito Marino F, Buono S, Montella M, Giannatiempo R, Messina F, Casaretta G, Arpino G, Vita G, Fiorentino F, Insabato L, Sgambato A, Orditura M, Franco R, Accardo M. Zito Marino F, et al. Among authors: orditura m. J Pathol Clin Res. 2023 Sep;9(5):367-377. doi: 10.1002/cjp2.324. Epub 2023 May 4. J Pathol Clin Res. 2023. PMID: 37143440 Free PMC article.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi GV, Del Mastro L, Paris I, Montemurro F, Allegrini G, Colleoni M, Tamberi S, Zamagni C, Cazzaniga ME, Orditura M, Guarneri V, Castelletti D, Benelli M, Di Marino M, Arpino G, De Laurentiis M. Malorni L, et al. Among authors: orditura m. Eur J Cancer. 2023 Jun;186:1-11. doi: 10.1016/j.ejca.2023.03.001. Epub 2023 Mar 8. Eur J Cancer. 2023. PMID: 37003098 Free article. Clinical Trial.
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.
Iovino F, Diana A, Carlino F, Ferraraccio F, Antoniol G, Fisone F, Perrone A, Zito Marino F, Panarese I, Tathode MS, Caraglia M, Gatta G, Ruggiero R, Parisi S, De Vita F, Ciardiello F, Docimo L, Orditura M. Iovino F, et al. Among authors: orditura m. J Clin Med. 2022 Nov 26;11(23):6987. doi: 10.3390/jcm11236987. J Clin Med. 2022. PMID: 36498560 Free PMC article.
128 results